Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
Type:
Grant
Filed:
April 30, 2021
Date of Patent:
January 16, 2024
Assignees:
Novartis AG, The Trustees of the University of Pennsylvania
Inventors:
Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Walter Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Patricia Pinto Guimaraes, Saar Gill, Marco Ruella, Regina M. Young
Abstract: The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.
Type:
Grant
Filed:
September 22, 2020
Date of Patent:
January 9, 2024
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Jamie M. Orengo, Jeanne Allinne, Andrew J. Murphy, George D. Yancopoulos
Abstract: This application relates to a pharmaceutical composition for use in a method for treating and/or preventing a patient having ectopic ossification and/or brain tumor, wherein the patient has an active mutation in ALK2 protein which is responsible for ectopic ossification or brain tumor; an amino acid residue at position 330 of ALK2 is proline; and an active ingredient of this composition is an anti-ALK2 antibody or an antigen-binding fragment thereof comprising a property of binding to ALK2, a property of cross-linking ALK2, and a property of inhibiting BMP signal transduction.
Type:
Grant
Filed:
March 4, 2019
Date of Patent:
January 2, 2024
Assignees:
Saitama Medical University, Daiichi Sankyo Company, Limited
Abstract: The invention relates to anti-human follicle-stimulating hormone receptor antibodies. The invention also relates to use of the anti-human follicle-stimulating hormone receptor antibodies in the treatment of cancer. The present invention also relates to a process for detecting cancerous cells and a process for diagnosis cancer. The present invention finds an application in the therapeutic and diagnostic medical technical fields.
Abstract: The present disclosure provides methods comprising a glucagon receptor antagonist in combination with an immunotherapeutic agent for treatment of disease.
Abstract: Provided herein are agents that inhibit the function (e.g., the ability to repress Tsp-1) of Protease, Serine 2 (PRSS2) by inhibiting the binding of PRSS2 to LRP1. Further provided herein are agents that bind to binding domain I of LRP1 and mimic the activity of prosaposin in stimulating Tsp-1 Methods of using these agents in treating cancer are also provided.
Abstract: Provided are oligomeric compounds, methods, and pharmaceutical compositions for DMPK the amount or activity of DMPK RNA in a cell or animal, and in certain instances reducing the amount of DMPK protein in a cell or animal. Such oligomeric compounds, methods, and pharmaceutical compositions are useful to treat type 1 myotonic dystrophy.
Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.
Type:
Grant
Filed:
March 16, 2021
Date of Patent:
December 5, 2023
Assignees:
Novartis AG, Beth Israel Deaconess Medical Center, Inc.
Inventors:
Anthony Rosenzweig, Jason D. Roh, David J. Glass
Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.
Abstract: The present disclosure relates to novel anti-CLEC2D antibodies and related compositions and methods of use thereof. These antibodies are used as therapeutics, and in prognostic and diagnostic applications in various cancers and other diseases.
Abstract: The invention provides methods of treating cancer, such as myeloid malignancies including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with nonfucosylated anti-CD70 antibodies.
Abstract: A method for reducing the viscosity of a pharmaceutical formulation is provided that utilizes a viscosity-reducing concentration of an excipient selected from the group consisting of the n-acetyl arginine, n-acetyl lysine, n-acetyl proline and mixtures thereof in combination with a therapeutiv protein. A stable pharmaceutical formulation is also provided.
Type:
Grant
Filed:
October 22, 2015
Date of Patent:
November 14, 2023
Assignee:
AMGEN INC.
Inventors:
Christopher James Sloey, Sekhar Kanapuram
Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
Type:
Grant
Filed:
January 8, 2021
Date of Patent:
November 14, 2023
Assignees:
BIONTECH SE, GENMAB A/S
Inventors:
Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.
Type:
Grant
Filed:
September 20, 2018
Date of Patent:
November 14, 2023
Assignees:
The University of British Columbia, Sangamo Therapeutics France
Inventors:
Li Zhou, Tobias Abel, François Meyer, Megan Levings, Nicolas Dawson, Caroline Lamarche
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Grant
Filed:
March 16, 2023
Date of Patent:
October 24, 2023
Assignee:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Grant
Filed:
March 16, 2023
Date of Patent:
October 24, 2023
Assignee:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Grant
Filed:
September 29, 2022
Date of Patent:
October 17, 2023
Assignee:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
Abstract: Presented herein are systems and methods for developing classifiers useful for predicting response to particular treatments. For example, in some embodiments, the present disclosure provides a method of treating subjects suffering from an autoimmune disorder, the method comprising administering an alternative to anti-TNF therapy to subjects who have been determined to be non-responsive via a classifier established to distinguish between responsive and non-responsive prior subjects in a cohort who have received the anti-TNF therapy.
Type:
Grant
Filed:
August 4, 2022
Date of Patent:
October 10, 2023
Assignee:
SCIPHER MEDICINE CORPORATION
Inventors:
Susan Ghiassian, Theodore R. Mellors, Marc Santolini, Asher Ameli, Nancy Schoenbrunner, Viatcheslav R. Akmaev, Keith J. Johnson
Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.
Type:
Grant
Filed:
February 5, 2021
Date of Patent:
October 10, 2023
Assignee:
BIOTEST AG
Inventors:
Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
Abstract: The invention provides an anti-CEA antibody for use in detecting CEA, treating disorders associated with CEA expression, diagnosing cancers characterized by aberrant CEA expression, and predicting effectiveness of cancer drug therapies.